Preoperative, Proton- Radiotherapy Combined With Chemotherapy for Borderline Resectable Pancreatic Cancer — PARC  

Pancreatic Cancer Clinical Trial

Official title: Preoperative, Proton- Radiotherapy Combined With Chemotherapy for Borderline Resectable Pancreatic Cancer

Status Recruiting

Clinical Trial Summary

This is an interventional, single arm, open-label, feasibility trial with gemcitabine and nab-paclitaxel, followed by concomitant proton therapy and capecitabine, followed by re-evaluation and surgery (when feasible) for patients with borderline resectable pancreatic cancer.

Clinical Trial Description

This is an interventional, single arm, open label, feasibility trial of preoperative chemotherapy + concomitant chemo-proton therapy followed by surgery (when feasible) for patients with borderline resectable pancreatic cancer. Aim of this study is to test referral and enrollment procedures as well as technical feasibility. Proton therapy will be delivered in MedAustron, which is a stand alone facility. Pancreatic cancer patients are typically complex cases that require multidisciplinary care. Moreover delivery of high dose of proton therapy to large volumes including the upper abdomen lymphnodes and pancreatic neural plexus is technically challenging, therefore a feasibility study is deemed necessary. Following this study, a larger study will be performed aiming to confirm the ability of preoperative chemotherapy + concomitant chemo-proton therapy to improve resectability and ultimately outcome of borderline resectable pancreatic cancer without increase in toxicity. ;

Related Conditions & MeSH terms

• Pancreatic Cancer
• Pancreatic Neoplasms
• Proton Therapy

• NCT number: NCT04894643
• Study type: Interventional
• Source: EBG MedAustron GmbH
• Contact: Piero Fossati, M.D.
• Phone: +43 664 80878
• Email: piero.fossati@medaustron.at
• Status: Recruiting
• Phase: N/A
• Start date: September 14, 2020
• Completion date: December 31, 2026